Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and vibrators.
Popular Articles

Remuda Ranch Programs For Eating And Anxiety Disorders Reports Need For Increasing Awareness Of Eating Disorders In Males
As many as five to ten million males in the U.S. struggle quietly with an eating disorder because they"re ashamed to admit they have the illness, reports Remuda Ranch Programs for Eating and Anxiety Disorders. Healthcare professionals, family members and close friends often are unaware of the high-risk behaviors in males that may signify an eating disorder. Therefore, effective intervention is often not available to the male population.
buy viagra
New Taxes Could Help Pay For Reform, But Would Cost Political Capital
Two new taxes that could help pay for health care reform both carry political baggage. The first, a possible new tax on at least some employer-sponsored health benefits, has support from members of Congress on both sides of the aisle. But during last year"s presidential campaign, President Obama spoke out strongly against just such a plan when his opponent, Sen. John McCain suggested it, Roll Call reports. "Within weeks, Obama may find himself hawking around the country legislation that includes a provision he so ardently rejected during the campaign. Obama didn"t just oppose the exclusion. He all but drew a "read my lips" line in the sand ... "For the first time in American history, [McCain] wants to tax your health benefits," Obama said on the campaign trail. "Apparently, Sen. McCain doesn"t think it"s enough that your health premiums have doubled"" (Koffler, 6/4).
News of the day
What Is Herpes? What Is Genital Herpes?
Genital herpes is a sexually transmitted infected caused by HSV (herpes simplex virus). This virus affects the genitals, the cervix, as well as the skin in other parts of the body. There are two types of herpes simplex viruses: a) HSVp1, or Herpes Type 1, and b) HSV-2, or Herpes Type 2.
Endocrinology

GlaxoSmithKline Pledges $97M Investment In AIDS Drugs For Africa, Allows South African Drugmaker To Produce Generic Second-Line Treatment

GlaxoSmithKline (GSK) on Tuesday announced plans to invest $97 million over 10 years "to improve research, development and access to AIDS drugs in Africa," Reuters reports. GSK also put forth "a new free voluntary licensing agreement for AIDS drug abacavir, or Ziagen with South African generic drugmaker Aspen Pharmacare." According to Reuters, Aspen will be able to "manufacture a cheaper generic version of the drug." GSK"s "latest stepsò€¦follow pressure from campaigners and some governments for drug companies to do more to get life-saving medicines to the poor, particularly in sub-Saharan Africa," Reuters writes. "Glaxo took a lead in February by promising to place many of its patents on drugs for tropical diseases into a free "pool," but it stopped short of offering patents on medicines for HIV/AIDS, which it does not consider to be a neglected disease" (Hirschler, 7/14). "The plans follow GSK"s historic deal in April with rival Pfizer to create a new HIV and AIDS company with 11 products," the Telegraph reports. The announcement is an "indication of the commitment that the new company will bring to fighting HIV/AIDS in the world"s poorest countries," GSK"s chief executive Andrew Witty said during a trip to Kenya (Ruddick, 7/14). Abacavir is "a "second line" antiretroviral therapy used when patients fail to respond to" standard treatment, the Financial Times reports. "The new pledges for the first time expand the waiver on rights to abacavir, and [Witty] stressed they also applied to supplies to low-income countries outside Africa provided the generic manufacturers could meet the criteria of "quality, capacity and sustainability"," the Financial Times writes. The newspaper reports that Witty does not support a patent pool for HIV drugs, and "[h]e said GSK had "a good track record" of making its medicines affordable in [middle income] countries through discounts" (Jack, 7/15). "While welcoming the initiatives, [British members of Parliament] and campaigners said GSK, and other pharmaceutical companies, must do more," the Guardian reports. "David Borrow, who chairs the all-party parliamentary group on AIDS, said: "GSK is taking positive steps, but they are broadly unilateral, which will limit their impact."ò€¦"The most effective way to reduce prices would be a patent pool approach, rather than individual deals between companies." A report released by Borrow"s group, titled, "The Treatment Timebomb," estimates that by 2030 more than 50 million people will need HIV treatment compared to just 9 million today (Kollewe, 7/14). Barrow said in a separate Guardian article, "We must reduce the price of second-line medicines and less toxic first-line medicines before millions need them. We cannot sleepwalk into a situation where we can only afford to treat a tiny proportion of those infected" (Boseley, 7/12). GSK"s pledge of $97 million will be put toward non-governmental organizations that work to prevent mother-to-child transmission of HIV and public-private partnerships for the development of pediatric HIV/AIDS drugs (GSK release, 7/14). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009